Digital Biomarkers Market Size, Share, and Trends 2026 to 2035

Digital Biomarkers Market (By System Component: Data Collection Tools, Data Integration Systems; By Application: Sleep & Movement Disease, Cardiovascular Diseases, Respiratory Disease, Neurodegenerative Disorders, Diabetes, Gastrointestinal Disease, Psychiatric Disorder, Others; By Clinical Practice: Diagnostic Digital Biomarkers, Monitoring Digital Biomarkers, Predictive And Prognostic Digital Biomarkers, Other's (Safety, Pharmaco dynamics/ Response, Susceptibility); By End-use: Healthcare Companies, Healthcare Providers, Payers, Others (Patient, caregivers)) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035

Last Updated : 27 Jan 2026  |  Report Code : 1537  |  Category : Healthcare   |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Digital Biomarkers Market 

5.1. COVID-19 Landscape: Digital Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Digital Biomarkers Market, By System Component

8.1. Digital Biomarkers Market, by System Component Type

8.1.1. Data Collection Tools

8.1.1.1. Market Revenue and Forecast

8.1.2. Data Integration Systems

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Digital Biomarkers Market, By Application

9.1. Digital Biomarkers Market, by Application

9.1.1. Sleep & Movement Disease

9.1.1.1. Market Revenue and Forecast

9.1.2. Cardiovascular Diseases

9.1.2.1. Market Revenue and Forecast

9.1.3. Respiratory Disease

9.1.3.1. Market Revenue and Forecast

9.1.4. Neurodegenerative Disorders

9.1.4.1. Market Revenue and Forecast

9.1.5. Diabetes

9.1.5.1. Market Revenue and Forecast

9.1.6. Gastrointestinal Disease

9.1.6.1. Market Revenue and Forecast

9.1.7. Psychiatric Disorder

9.1.7.1. Market Revenue and Forecast

9.1.8. Others

9.1.8.1. Market Revenue and Forecast

Chapter 10. Global Digital Biomarkers Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by System Component

10.1.2. Market Revenue and Forecast, by Application

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by System Component

10.1.3.2. Market Revenue and Forecast, by Application

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by System Component

10.1.4.2. Market Revenue and Forecast, by Application

10.2. Europe

10.2.1. Market Revenue and Forecast, by System Component

10.2.2. Market Revenue and Forecast, by Application

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by System Component

10.2.3.2. Market Revenue and Forecast, by Application

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by System Component

10.2.4.2. Market Revenue and Forecast, by Application

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by System Component

10.2.5.2. Market Revenue and Forecast, by Application

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by System Component

10.2.6.2. Market Revenue and Forecast, by Application

10.3. APAC

10.3.1. Market Revenue and Forecast, by System Component

10.3.2. Market Revenue and Forecast, by Application

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by System Component

10.3.3.2. Market Revenue and Forecast, by Application

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by System Component

10.3.4.2. Market Revenue and Forecast, by Application

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by System Component

10.3.5.2. Market Revenue and Forecast, by Application

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by System Component

10.3.6.2. Market Revenue and Forecast, by Application

10.4. MEA

10.4.1. Market Revenue and Forecast, by System Component

10.4.2. Market Revenue and Forecast, by Application

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by System Component

10.4.3.2. Market Revenue and Forecast, by Application

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by System Component

10.4.4.2. Market Revenue and Forecast, by Application

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by System Component

10.4.5.2. Market Revenue and Forecast, by Application

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by System Component

10.4.6.2. Market Revenue and Forecast, by Application

10.5. Latin America

10.5.1. Market Revenue and Forecast, by System Component

10.5.2. Market Revenue and Forecast, by Application

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by System Component

10.5.3.2. Market Revenue and Forecast, by Application

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by System Component

10.5.4.2. Market Revenue and Forecast, by Application

Chapter 11. Company Profiles

11.1. Bayer AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Biogen Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. ActigraphLLc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Amgen Inc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. F. Hoffmann-La Roche Ltd

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Fitbit Inc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. GlaxoSmithKline Plc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Koninklijke Philips N.V.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Mindstrong Health

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Medical Care Corporation

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : According to Precedence Research, the global digital biomarkers market size was reached at USD 5.04 billion in 2025 and is anticipated to surpass over USD 36.98 billion by 2035.

Answer : The global digital biomarkers market is expected to drive growth at a CAGR of 22.05% from 2026 to 2035.

Answer : The global digital biomarkers market is primarily driven by the rising usage of the digital biomarkers across various applications such as diabetes, respiratory diseases, CVDs, and sleep disorders.

Answer : The major players operating in the digital biomarkers market are Bayer AG, Biogen Inc., ActigraphLLc, Amgen Inc, F. Hoffmann-La Roche Ltd, Fitbit Inc, GlaxoSmithKline Plc, Koninklijke Philips N.V., Mindstrong Health, Medical Care Corporation, Medopad Ltd.

Answer : North America dominated the global digital biomarkers market, accounting for around 58.45% of the market share in 2025 and will lead the market in the near future.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client